DUBLIN–(BUSINESS WIRE)–The “Global Acute Lymphoblastic Leukemia Therapeutics Market: Focus on Cell Type, Therapy Type, and Over 10 Countries’ Data – Analysis and Forecast, 2024-2033” report has been added to ResearchAndMarkets.com’s offering.
Acute lymphoblastic leukemia (ALL), also known as Acute Lymphocytic Leukemia or Acute Lymphoid Leukemia, is a malignant disease affecting the bone marrow and blood. It is characterized by the excessive proliferation of early lymphoid precursors, leading to the displacement of normal hematopoietic cells in the marrow. ALL is the most prevalent type of cancer and leukemia among children in the U.S.
The global market for Acute Lymphoblastic Leukemia (ALL) is witnessing a dynamic landscape with growing number of cases. Among the various reasons identified, sedentary lifestyle and unhealthy eating habits are more commonly associated with the disease. Furthermore, prevalence is estimated to increases in coming years owing to increased awareness about preventive care and diagnostics.
The current acute lymphoblastic leukemia market demonstrates moderate competitiveness, featuring established major players alongside mid-sized companies. Given the increasing emphasis of numerous pharmaceutical companies on oncology, the market is expected to witness entry of new small-sized companies in the foreseeable future.
Key Questions Answered in the Report
- What is the present size of the global acute lymphoblastic leukemia therapeutics (ALL) market?
- Who are the major contributors in the global ALL therapeutics market?
- Which region is experiencing the most rapid growth in the global ALL therapeutics market?
- Which geographical area holds the largest portion of the global ALL therapeutics market?
- What is the projected Compound Annual Growth Rate (CAGR) for the ALL therapeutics market?
- What are the primary factors propelling growth in the ALL therapeutics market?
- What are critical factors posing challenge to the growth of global ALL therapeutics market?
- Which sector is predicted to spearhead the global ALL therapeutics market by 2033?
Competitive Benchmarking & Company Profiles
- AbbVie Inc.
- DAIICHI SANKYO COMPANY, LIMITED.
- Amgen Inc.
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Erytech Pharma Inc.
- Fate Therapeutics
- F. Hoffmann-La Roche Ltd
- Genmab A/S
- Gilead Sciences, Inc.
- GSK plc.
- Jazz Pharmaceuticals, Inc.
- Juventas Cell Therapy Ltd.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi
- Seagen Inc.
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Key Topics Covered:
Executive Summary
Scope and Definition
1 Markets
1.1 Trends: Current and Future Impact Assessment
1.1.1 Sample Text
1.1.2 Trend 1- Increased Number of ALL Cases
1.1.3 Trend 2- Focus on Addressing Treatment Induced Side-effects
1.1.4 Trend 3- Focus on Preventive Care
1.2 Supply chain Overview
1.2.1 Value Chain Analysis
1.2.2 Market Map
1.2.3 Pricing Forecast for Raw Materials and Components
1.3 Research and Development Review
1.3.1 Patent Filing Trend (by Country, Company)
1.4 Clinical Trial Landscape
1.4.1 Clinical Landscape (by Development Stage)
1.4.2 Clinical Landscape (by Drug Class)
1.5 Regulatory Landscape
1.6 Stakeholder Analysis
1.6.1 Use case
1.6.2 End User and Buying Criteria
1.7 Impact Analysis for Key Global Events- Covid19
1.8 Market Dynamics Overview
1.8.1 Market Drivers
1.8.2 Market Restraints
1.8.3 Market Opportunities
1.9 Reimbursement Scenario
2 Application
2.1 Application Segmentation
2.2 Application Summary
2.3 Global Acute Lymphoblastic Leukemia Therapeutics Market (by Cell Type)
2.3.1 B-cell ALL
2.3.2 T-cell ALL
2.3.3 Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
3 Products
3.1 Product Segmentation
3.2 Product Summary
3.3 Global Acute Lymphoblastic Leukemia Therapeutics Market (by Products and Services)
3.3.1 Chemotherapy
3.3.2 Targeted Therapy
3.3.3 Radiation Therapy
3.3.4 Stem Cell Transplantation
4 Regions
4.1 Regional Summary
4.2 Drivers and Restraints
4.3 North America
4.3.1 Regional Overview
4.3.2 Driving Factors for Market Growth
4.3.3 Factors Challenging the Market
4.3.4 Application
4.3.5 Product
4.3.6 U.S.
4.3.7 U.S. Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.3.8 U.S. Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.3.9 Canada
4.3.10 Canada Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.3.11 Canada Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.4 Europe
4.4.1 Regional Overview
4.4.2 Driving Factors for Market Growth
4.4.3 Factors Challenging the Market
4.4.4 Application
4.4.5 Product
4.4.6 France
4.4.7 France Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.4.8 France Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.4.9 Germany
4.4.10 Germany Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.4.11 Germany Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.4.12 U.K.
4.4.13 U.K. Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.4.14 U.K. Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.4.15 Rest of Europe
4.4.16 Rest of Europe Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.4.17 Rest of Europe Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.5 Asia Pacific
4.5.1 Regional Overview
4.5.2 Driving Factors for Market Growth
4.5.3 Factors Challenging the Market
4.5.4 Application
4.5.5 Product
4.5.6 China
4.5.7 China Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.5.8 China Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.5.9 India
4.5.10 India Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.5.11 India Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.5.12 Japan
4.5.13 Japan Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.5.14 Japan Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.5.15 Rest-of-Asia-Pacific
4.5.16 Rest-of-Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.5.17 Rest-of-Asia-Pacific Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.6 Rest-of-the-World
4.6.1 Regional Overview
4.6.2 Driving Factors for Market Growth
4.6.3 Factors Challenging the Market
4.6.4 Application
4.6.5 Product
4.6.6 The Middle East and Africa
4.6.7 The Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.6.8 The Middle East and Africa Acute Lymphoblastic Leukemia Therapeutics Market by Product
4.6.9 Latin America
4.6.10 Latin America Acute Lymphoblastic Leukemia Therapeutics Market by Application
4.6.11 Latin America Acute Lymphoblastic Leukemia Therapeutics Market by Product
5 Markets – Competitive Benchmarking & Company Profiles
5.1 Next Frontiers…
5.2 Geographic Assessment
5.2.1 Overview
5.2.2 Top Products / Product Portfolio
5.2.3 Top Competitors
5.2.4 Target Customers
5.2.5 Key Personnel
5.2.6 Analyst View
5.2.7 Market Share
For more information about this report visit https://www.researchandmarkets.com/r/sa6pst
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900